Does CANAGLIFLOZIN Cause Product packaging quantity issue? 16 Reports in FDA Database
Boost Your Natural Energy & Metabolism
Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.
According to the FDA Adverse Event Reporting System (FAERS), 16 reports of Product packaging quantity issue have been filed in association with CANAGLIFLOZIN (INVOKANA). This represents 0.1% of all adverse event reports for CANAGLIFLOZIN.
16
Reports of Product packaging quantity issue with CANAGLIFLOZIN
0.1%
of all CANAGLIFLOZIN reports
0
Deaths
0
Hospitalizations
How Dangerous Is Product packaging quantity issue From CANAGLIFLOZIN?
Of the 16 reports.
Is Product packaging quantity issue Listed in the Official Label?
This adverse event is not currently listed in the official FDA drug label for CANAGLIFLOZIN. However, 16 reports have been filed with the FAERS database.
What Other Side Effects Does CANAGLIFLOZIN Cause?
Diabetic ketoacidosis (3,413)
Toe amputation (2,193)
Osteomyelitis (2,146)
Acute kidney injury (1,853)
Fungal infection (1,385)
Gangrene (1,081)
Weight decreased (1,014)
Cellulitis (1,007)
Urinary tract infection (920)
Diabetic foot infection (832)
What Other Drugs Cause Product packaging quantity issue?
LEUPROLIDE (523)
ALBUTEROL (431)
BUDESONIDE\FORMOTEROL (301)
FENTANYL (286)
BUPRENORPHINE (225)
CYCLOSPORINE (206)
ESTRADIOL (201)
BIMATOPROST (177)
RIVAROXABAN (174)
EXENATIDE (154)
Which CANAGLIFLOZIN Alternatives Have Lower Product packaging quantity issue Risk?
CANAGLIFLOZIN vs CANAGLIFLOZIN\METFORMIN
CANAGLIFLOZIN vs CANAKINUMAB
CANAGLIFLOZIN vs CANDESARTAN
CANAGLIFLOZIN vs CANDESARTAN CILEXETIL
CANAGLIFLOZIN vs CANDESARTAN CILEXETIL\HYDROCHLOROTHIAZIDE